Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,550
  • Shares Outstanding, K 162,440
  • Annual Sales, $ 12,740 K
  • Annual Income, $ -93,030 K
  • 36-Month Beta 2.36
  • Price/Sales 5.51
  • Price/Cash Flow N/A
  • Price/Book 0.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings -0.03 on 03/07/18
  • Next Earnings Date 08/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.41 +3.73%
on 08/14/18
0.55 -22.67%
on 07/17/18
-0.08 (-16.61%)
since 07/16/18
3-Month
0.41 +3.73%
on 08/14/18
0.70 -39.24%
on 05/18/18
-0.27 (-39.24%)
since 05/16/18
52-Week
0.41 +3.73%
on 08/14/18
3.26 -86.95%
on 10/09/17
-1.98 (-82.35%)
since 08/16/17

Most Recent Stories

More News
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.

CLDX : 0.43 (+2.38%)
LLY : 104.62 (+1.25%)
SGEN : 74.33 (+0.58%)
BMY : 61.10 (+1.39%)
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 0.43 (+2.38%)
Celldex Provides Corporate Update and Reports Second Quarter 2018 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018. The Company will host a conference call at 4:30 p.m. ET today to provide...

CLDX : 0.43 (+2.38%)
Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call

Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference...

CLDX : 0.43 (+2.38%)
Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN),...

BZH : 12.83 (+2.80%)
CLDX : 0.43 (+2.38%)
IDTI : 36.15 (+0.70%)
LPX : 29.57 (+1.34%)
MYGN : 42.01 (+0.53%)
CRL : 120.65 (+1.52%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.

CLDX : 0.43 (+2.38%)
BLUE : 156.10 (+1.17%)
BDSI : 2.90 (+10.27%)
BMY : 61.10 (+1.39%)
Initiating Free Research Reports on Celgene and Three Other Biotech Equities

Stock Research Monitor: CARA, CLDX, and CORT

CARA : 18.81 (+1.73%)
CLDX : 0.43 (+2.38%)
CELGZ : 1.49 (+2.05%)
Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks

Stock Research Monitor: CALA, CARA, and CLDX

CARA : 18.81 (+1.73%)
CELG : 90.18 (+1.02%)
CLDX : 0.43 (+2.38%)
CALA : 4.70 (+1.08%)
CELGZ : 1.49 (+2.05%)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing...

CLDX : 0.43 (+2.38%)
JNCE : 7.48 (+0.27%)
IDRA : 9.16 (+0.11%)
RCUS : 13.20 (+1.77%)
BLCM : 6.41 (+3.05%)
INO : 4.49 (+1.35%)
FATE : 11.01 (+1.76%)
MRTX : 58.65 (+0.69%)
SRNE : 5.28 (+4.55%)
MOR : 28.40 (+0.92%)
AGEN : 1.70 (+0.59%)
INCY : 67.75 (+1.32%)
ZYME : 14.10 (+0.71%)
NK : 3.15 (+2.27%)
PIRS : 5.34 (+3.09%)
NLNK : 2.76 (+0.72%)
Innovative Biotech Companies, Preparing for the Future

LAS VEGAS, NV / ACCESSWIRE / June 15, 2018 / Some innovative biotechnology companies that are working on ground-breaking technology and are prepared for the future include: Propanc Biopharma, Inc. (OTCQB:...

CLDX : 0.43 (+2.38%)
PPCHD : 1.2000 (+20.00%)
AQXP : 3.05 (+7.02%)
PPCB : 0.0069 (-21.59%)
CPRX : 2.89 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 0.45
1st Resistance Point 0.43
Last Price 0.43
1st Support Level 0.41
2nd Support Level 0.41

See More

52-Week High 3.26
Fibonacci 61.8% 2.17
Fibonacci 50% 1.84
Fibonacci 38.2% 1.50
Last Price 0.43
52-Week Low 0.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar